Medical management of lung cancer: Experience in China.
Beijing, China. In Thorac Cancer, Jan 2015
For those with active epidermal growth factor receptor (EGFR) mutation, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are used in first-, second- or third-line and maintenance treatment of non-small cell lung cancer (NSCLC).
Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.
Yinchuan, China. In Biomed Res Int, Dec 2014
Several molecular pathways underlying mechanisms of this disease have been partly elucidated, among which the epidermal growth factor receptor (EGFR) pathway is one of the well-known signaling cascades that plays a critical role in tumorigenesis.
Toronto, Canada. In J Immunother Cancer, Dec 2014
Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy.
Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.
More papers using
Toyonaka, Japan. In Lung Cancer Int, 2011
The patients were evaluated including the following information: age, gender, histology of lung cancer, performance status, smoking status, epidermal growth factor receptor (EGFR) mutation status, liver metastasis, viral hepatitis, alcoholic liver injury, clinical response, and hepatotoxicity due to EGFR tyrosine kinase inhibitors.
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
In PLoS ONE, 2009
... CA), ER (SP1, prediluted, Ventana Medical Systems, Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, ... Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation.
In PLoS ONE, 2006
... antibody against phospho-IκBα, IκBα, phospho-IKKα/β, IKKα, IKKβ, phospho-p38, p38, phospho-MKK3/6, MKK3, phospho-Akt, Akt, phospho-EGFR and EGFR were purchased from Cell Signaling (MA, USA) ... Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex
In Breast cancer research : BCR, 2003
... used in this study: extracellular signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, total β-catenin, poly(ADP-ribose)polymerase (PARP), EGFR, p-EGFR (tyrosine [Tyr] 845), and p-Tyr-100 (Cell Signaling Technology, Inc., Danvers, MA, ... Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
In PLoS ONE, 2002
... (Abcam, ab654), Glut3 (made in Devaskar's lab, UCLA), Glut1 (Abcam, ab15309), IGFR (Cell Signaling, 111A9), EGFR, (Santacruz, sc 03, 1005), Glucose-6-P dehydrogenase (Abcam, ab34436), Protein Kinase C-zeta ... Can correct protein models be identified?
In Molecular Immunology, 2002
... removed with xylene from sections and immunohistochemistry was performed using the FDA-approved in vitro diagnostic EGFR pharm Dx™ (DAKO, Glostrup, Denmark) and HercepTest ... Protein tyrosine phosphorylation influences adhesive junction assembly and follicular organization of cultured thyroid epithelial cells
In British Journal of Cancer, 1996
... -catenin, and p120 (Transduction Laboratories, California, USA), phosphorylated MARCKS (Cell Signaling, Massachusetts, USA), phosphorylated EGFR (Cell Signaling, Massachusetts, USA), and EGFR ...